Randomized Comparison of Doxorubicin Alone Versus Ifosfamide Plus Doxorubicin or Mitomycin, Doxorubicin, and Cisplatin Against Advanced Soft Tissue Sarcomas.

Journal of Clinical Oncology - United States
doi 10.1200/jco.1993.11.7.1269
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)

Related search

Cisplatin Versus Cisplatin Plus Doxorubicin for Standard-Risk Hepatoblastoma

New England Journal of Medicine
Medicine
2009English

Randomized Phase II Study of the PDGFRα Antibody Olaratumab Plus Liposomal Doxorubicin Versus Liposomal Doxorubicin Alone in Patients With Platinum-Refractory or Platinum-Resistant Advanced Ovarian Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Systemic Complications of the Bidirectional Intraoperative Chemotherapy With Intravenous Ifosfamide and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Using Cisplatin Plus Doxorubicin

Pleura and Peritoneum
Internal Medicine
2019English

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced and or Metastatic Bilharzial Urothelial Carcinoma of the Bladder in Egypt.

Research in Oncology
2011English

Sequential Methotrexate and 5-Fluorouracil, Doxorubicin, and Cisplatin for Advanced Urothelial Cancer

Japanese Journal of Urology
Urology
1992English

Doxorubicin and 5-Fluorouracil Versus Doxorubicin and Oral Ftorafur in the Treatment of Advanced Gastric Cancer—a Phase II and III Trial

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
1990English

High-Dose Epirubicin Is Not an Alternative to Standard-Dose Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas. A Study of the EORTC Soft Tissue and Bone Sarcoma Group

British Journal of Cancer
Cancer ResearchOncology
1998English

Safety and Efficacy of Combination Therapy With Apatinib and Doxorubicin in Metastatic Soft Tissue Sarcomas: An Observational Study From Multiple Institutions

Cancer Management and Research
Oncology
2019English

Cisplatin and Doxorubicin Induce Distinct Mechanisms of Ovarian Follicle Loss; Imatinib Provides Selective Protection Only Against Cisplatin

PLoS ONE
Multidisciplinary
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy